头颈癌免疫治疗处方模式与免疫相关不良事件
2254例(4.8%)在诊断后12个月内接受免疫治疗,处方率从2017年2.3%微增至2022年2.8%。90天总体免疫相关不良事件(irAE)发生率为41.2%,严重irAE为2.7%。
要点
- 头颈癌免疫治疗处方率低且增长缓慢,2022年仅2.8%。
- 帕博利珠单抗占主导,2022年市场份额达87%。
- 90天irAE发生率41.2%,严重irAE仅2.7%。
核心结论
- 帕博利珠单抗主导免疫治疗市场,但65岁以下头颈癌患者免疫治疗相对使用率自FDA批准以来仅轻微增加。
- 免疫相关不良事件常见且与关键个体合并症相关,严重irAE罕见且与整体合并症状态相关。
研究设计与样本
- 回顾性队列研究,使用MarketScan商业和多州医疗补助数据库,纳入2016年1月1日至2022年12月31日头颈癌患者。
- 纳入标准:ICD-10-CM诊断头颈癌,诊断前保险入组至少6个月,随访至少1个月;数据库排除65岁及以上患者。
主要发现
- 免疫治疗处方率从2017年2.3%略增至2022年2.8%(变化0.5%;95%CI,0.1%-0.9%)。
- 帕博利珠单抗和纳武利尤单抗初始处方模式相似,2019年出现分化,至2022年帕博利珠单抗占87%市场份额。
- 90天总体irAE发生率为41.2%,严重irAE发生率为2.7%。
- 药物使用与irAE无关联;合并症评分与90天严重irAE相关(OR,1.02;95%CI,1.02-1.03)。
- 基线甲状腺功能减退(aOR,6.7;95%CI,5.0-9.0)和肝病(aOR,1.7;95%CI,1.1-2.7)与irAE发生独立相关。
临床怎么用
- 头颈癌患者接受免疫治疗前应评估基线甲状腺功能减退和肝病等合并症,以识别irAE高危人群。
- 尽管严重irAE发生率较低,但仍需对免疫治疗患者进行irAE监测。
局限性
- 研究基于索赔数据库,可能受编码准确性限制。
- 数据库排除65岁及以上患者,结论外推需谨慎。
- 回顾性设计可能残留混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Immunotherapy is approved for first-line treatment of recurrent/metastatic head and neck cancer (HNC). The prescribing patterns are largely unreported, and assessment of immune-related adverse events (irAEs) in patients with HNC is limited. OBJECTIVE: To assess the prescribing patterns of immunotherapy and the incidence and risk factors for irAEs using a claims-based database. DESIGN, SETTING, AND PARTICIPANTS: A retrospective cohort study of MarketScan Commercial and multistate Medicaid databases of all patients with HNC from January 1, 2016, to December 31, 2022, was performed. Inclusion criteria were patients with HNC, defined by International Statistical Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) codes with 6 months or longer of insurance enrollment prior to diagnosis and 1 or more months of follow-up. The databases excluded patients 65 years or older. Statistical analysis was conducted from October 1, 2024, through December 31, 2024. EXPOSURE: Prescription of an immunotherapeutic within 12 months after HNC diagnosis. OUTCOMES: The primary outcome measure was prescribing rate of immunotherapeutics overall and per year. The relative use of each immunotherapeutic was also explored. Secondary outcome measures were incidence of irAEs, severe irAEs, and univariable/multivariate risk factors for irAEs. RESULTS: A total of 47 365 patients with HNC were included, and 2254 (4.8%) of these patients received immunotherapy. Overall, 32 195 participants were male individuals (68%) and 14 607 were female individuals (32%), with a mean (SD) age of 54 (9) years. The rate of immunotherapy prescriptions slightly increased over time from 2.3% of patients with HNC in 2017 to 2.8% in 2022 (percent change, 0.5%; 95% CI, 0.1%-0.9%). Following initial approval by the US Food and Drug Administration (FDA), prescribing patterns of pembrolizumab and nivolumab were similar, but divergence in 2019 led to 87% of the market share dominated by pembrolizumab by 2022. The 90-day overall irAE-rate was 41.2% and severe irAE rate was 2.7%. There was no association between medication use and irAEs. Comorbidity score was associated with severe irAEs at 90 days (odds ratio [OR], 1.02; 95% CI, 1.02-1.03). Baseline hypothyroidism (adjusted OR [aOR], 6.7; 95% CI, 5.0-9.0) and liver disease (aOR, 1.7; 95% CI, 1.1-2.7) were independently associated with the development of irAEs. CONCLUSIONS: This cohort study found that pembrolizumab dominated the immunotherapy prescribing market, but the relative use of immunotherapy has minimally increased in patients younger than 65 years since FDA approval. irAEs were frequent and associated with key individual comorbidities. Severe irAEs were rare and associated with overall comorbidity status.
引用
- Peterson AM, Stwalley D, Kallogjeri D, et al. Immunotherapy Prescribing Patterns and Immune-Related Adverse Events in Patients With Head and Neck Cancer. JAMA Otolaryngol Head Neck Surg. 2026. PMID: 41712201. doi:10.1001/jamaoto.2025.5513
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。